Technical Articles

In the medical field, glioblastoma (GBM) has always been regarded as an extremely dangerous brain tumor. It not only has a high incidence rate, but also has a five-year survival rate of less than 5% and a median survival of only about 15 months. Despite the continuous advancement of modern medical technology, the survival of GBM patients has not been significantly improved. This tumor is highly resistant to immunotherapy, and its microenvironment is complex and filled with a large number of immunosuppressive cells, making traditional immunotherapy difficult to work.